HEALTH SECURITY SYSTEMS AUSTRALIA



HSSA Call for Expressions of Interest Collaborative Project Proposals for Medical Countermeasures, 2022



Supported by:







Acknowledgement of Country

DMTC acknowledges the First Nations Peoples of the land on which we work and meet. We acknowledge the Wurundjeri People of the Kulin nation, the Traditional Owners of Melbourne's east and outer-east, and pay our respects to their Elders past, present and emerging.

We also acknowledge the Traditional Custodians of country across

Australia and acknowledge their proud and enduring connection to land,

waters and culture.



About DMTC Ltd

DMTC is a not-for-profit Company that leads and manages multi-party collaborations involving government, industry and research partners to enhance Australia's industrial capacity and capability.


OUR VISION

To develop technology solutions and provide advice enabling industry to enhance Australian Defence and national security capability.



OUR MISSION


To create and enhance Australian industrial capability and skills through designing and executing collaborative technology development and innovation activities in the Defence, national security and related sectors.





DMTC Snapshot

- Creates and enhances Australian industrial capability
- Facilitates, leads and delivers collaborative research and development and innovation activities
- Specialises in the defence, national security and health security sectors
 - √ 10 programs / disciplines
 - √ 42 projects under management
 - ✓ 50+ industry & 20+ research partners
 - ✓ 38% of projects directly involve DSTG,15% involve CSIRO and 7% ANSTO
 - ✓ ISO 9001 and 44001 accredited
 - ✓ ISO 27001 compliant
 - ✓ DISP Accreditation



www.dmtc.com.au



Health Security Systems Australia

- HSSA formed as a Division of DMTC Ltd in July 2021
- The Division aims to build sovereign industrial and research capabilities for Australia aligned to national health security priorities

HSSA Mission:

Lead collaborative R&D programs for the protection of military and civilian personnel against Chemical, Biological, Radiological and Nuclear (CBRN) threats, emerging infectious diseases and pandemics



HSSA Mission Space

HSSA leads collaborative teams in 7 sectors to deliver the mission















Medical Countermeasures Initiative

- Therapeutics
- Vaccines
- Point-of-care diagnostics

Medical Devices

- Medical Monitors
- Autoinjectors etc.
- Treatment equipment

Hazard Management

- Area decon
- Personnel decon
- Equipment decon

CBR Modelling & Simulation

- Epidemiological
- Health & Economic
- CBRN dispersion
- Emergency Ops decision support tools

CBR Sensing Systems

- Wearable sensors
- Stand-off CBR detection

Personal Protective Equipment

- Masks
- Respirators
- Ventilators
- CBR protective clothing

Strategic Advisory

- Policy advisory
- NHSRA
- Health Security R&D and manufacture capability assessments



Medical Countermeasures Program

- Focused on the growth of national capability and capacity for the advanced R&D and manufacture of vaccines, therapeutics and diagnostics against chemical, biological and radiological threats, emerging infectious diseases and pandemics
- Since 2017 is supported by DSTG's Next Generation Technology Fund
 - Projects are expected to leverage cash and in-kind contributions from all partners
 - Not a 'Grant'
- This is the fifth call for expression of interest
- DMTC / HSSA role in operations and project management oversight



MCM Call-Out 2022 Expression of Interest



MCM 2022 Call-Out

- HSSA is currently seeing expressions of interest (EOI) for collaborative project proposals focussed on the following priority themes:
 - 1. Anti-infective therapeutics, including against antimicrobial resistance
 - 2. Vaccine products or platform technologies for infectious disease threats
 - 3. Medical Countermeasures against chemical threats
- EOIs must be targeted to one of the above themes, and submitted using the online registration form: Medical Countermeasures EOI Form 2022
- EOIs must include a completed, one-page QUAD Chart
- Due date for submissions: 11:59pm AEST 30 June 2022




MCM 2022 Call-Out Process

- The EOI is the first stage of the application process
- Following review by an internal panel, all applicants will be notified of the outcome of their application within 3 weeks of the closing date
 - Feedback is not provided on the EOI application
- Successful applicants from the first stage will be invited to respond to a Request for Proposal (RFP)
 - Templates and instructions provided at opening of RFP
- Following review by an internal panel, all applicants will be notified of the outcome of their application around 4 weeks after the closing date
 - Feedback is provided to unsuccessful applicants
- Successful applicants will enter into a DMTC Project Agreement



MCM 2022 Call-Out Process and Timeline (Guide)








- The EOI must focus on one of these priority themes:
 - 1. Anti-infective therapeutics, including against antimicrobial resistance
 - 2. Vaccine products or platform technologies for infectious disease threats
 - 3. Countermeasures against chemical threats
- The EOI Response must be provided on the QUAD Chart template
 - Instructions are included in the QUAD chart template
 - No more than one A4 page (submitted as pdf)
- Proposed project teams must comprise at least one industry partner and at least one academic partner



- Project stage Preliminary proof-of-concept should already be demonstrated.
- Examples
 - Biological target already identified and relevance demonstrated
 - Chemical threat identified and impact understood
 - In vitro efficacy demonstrated
 - Vaccine manufacturing process at lab-scale demonstrated
 - Small molecule hits synthesised and tested



- Project Stage at Start at or around TRL 3
- Technology Readiness Level (TRL) is used to estimate the maturity of a technology



- Reference to Technology Readiness Levels (TRL) is not required for the EOI, but will be required for the RFP
 - Further details and guidance will be provided for the RFP stage



- Allowed budget items
 - Personnel
 - Materials / Consumables
 - Travel (meetings, conferences)
- Each partner is expected to provide cash and/or in-kind contributions to leverage the investment from DMTC



- Project work is preferred to be conducted in Australia
 - An overseas partner may participate in a project if they offer a unique capability that is not available on-shore, but their contribution will be in-kind to the project and not reimbursable by DMTC
- Project Conditions Personnel
 - Personnel participating in the project should, where possible, be Australian citizens or have permanent residency status in Australia
 - Personnel that do not meet this requirement will require written approval (at DMTC's discretion) to participate



FAQs

- If you have any questions, please email <u>mcm.eoi@dmtc.com.au</u>
- FAQs can be found on our website (<u>EOI: Collaborative Project Proposals in Medical Countermeasures</u>)
 - FAQs will be updated periodically please check the website
- The webinar is being recorded and will be made available on our website while the EOI is open



a Division of DMTC Ltd

DMTC Ltd

Wurundjeri Country Level 1, 620 High Street Kew, VIC 3101, Australia

Contact Dr Julia Cianci Email mcm.eoi@dmtc.com.au

Web dmtc.com.au/health-security-systems Follow us on **LinkedIn** or on **Twitter** @DMTCLtd